MP11-12 REGIONAL LYMPH NODE METASTASIS ON PSMA PET CORRELATES WITH DECREASED BCR-FREE AND THERAPY-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Staging (MP11)1 Sep 2021MP11-12 REGIONAL LYMPH NODE METASTASIS ON PSMA PET CORRELATES WITH DECREASED BCR-FREE AND THERAPY-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY Christoph Wuernschimmel, Thomas Amiel, Matthias Heck, Thomas Horn, Noemi Nguyen, Lars Budaeus, Sophie Knipper, Mike Wenzel, Isabel Rauscher, Matthias Eiber, Hui Wang, and Tobias Maurer Christoph WuernschimmelChristoph Wuernschimmel More articles by this author , Thomas AmielThomas Amiel More articles by this author , Matthias HeckMatthias Heck More articles by this author , Thomas HornThomas Horn More articles by this author , Noemi NguyenNoemi Nguyen More articles by this author , Lars BudaeusLars Budaeus More articles by this author , Sophie KnipperSophie Knipper More articles by this author , Mike WenzelMike Wenzel More articles by this author , Isabel RauscherIsabel Rauscher More articles by this author , Matthias EiberMatthias Eiber More articles by this author , Hui WangHui Wang More articles by this author , and Tobias MaurerTobias Maurer More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001984.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To address the impact of preoperative PSMA PET (prostate specific membrane antigen positron emission tomography) findings prior to radical prostatectomy (RP) and pelvic lymph node dissection (PLND) on biochemical recurrence (BCR) and time to adjuvant or salvage treatment. METHODS: Between 2013 and 2017, 64 intermediate- and 166 high-risk prostate cancer (PCa) patients received 68Ga-PSMA-11 PET followed by RP and PLND. BCR-free and therapy-free survival was determined. For all time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied, with a significance threshold of p<0.05. RESULTS: Positive extraprostatic PSMA PET lesions were found in 4 (6.2%) intermediate-risk patients and 47 (28.3%) high-risk patients. 66 (28.7%) of all 230 patients harbored histopathologically positive lymph nodes (LN). Median follow up was 30.2 months. BCR occurred in 50.4% (n=116) of patients and adjuvant or salvage treatment was performed in 46.5% (n=107). Worst BCR-free and therapy-free survival was observed in pN1 patients who also exhibited PSMA PET positive LN, followed by pN1 patients without PSMA PET positive LN and patients without evidence of LN metastasis on histology and PSMA PET (median BCR-free survival 1.7 vs. 7.5 vs. >36 months, median therapy-free survival 2.6 vs. 8.9 vs. >36 months). CONCLUSIONS: Patients with positive LN on PSMA PET prior to RP have to expect early BCR and adjuvant/salvage therapy, despite thorough PLND. Therefore, results from PSMA PET can be used for patients´ consultation, more stringent follow-up as well as for planning of neo-/adjuvant therapy. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e182-e183 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christoph Wuernschimmel More articles by this author Thomas Amiel More articles by this author Matthias Heck More articles by this author Thomas Horn More articles by this author Noemi Nguyen More articles by this author Lars Budaeus More articles by this author Sophie Knipper More articles by this author Mike Wenzel More articles by this author Isabel Rauscher More articles by this author Matthias Eiber More articles by this author Hui Wang More articles by this author Tobias Maurer More articles by this author Expand All Advertisement Loading ...